sponsored links

Merck KGaA suffers setback on cancer drug

Sponsored Links

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

View full post on Health News Headlines – Yahoo! News


Sponsored Links
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

AddThis Social Bookmark Button

Leave a Reply

You must be logged in to post a comment.